Crystalline forms
Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
1. A crystalline form of zoledronic acid: DL-lysine.
2. The crystalline form of claim 1 , wherein said crystalline form is characterized by a powder X-ray diffraction pattern comprising powder X-ray diffraction peaks at about 6.6, 11.0, 14.2, 18.3, 19.7, 22.7 and 27.6 ±0.2 degrees 2-theta.
3. The crystalline form of claim 1 , wherein said crystalline form is characterized by a powder X-ray diffraction pattern comprising powder X-ray diffraction peaks at about 7.2, 14.0, 18.3, 19.1, 20.7, 24.6 and 34.4 ±0.2 degrees 2-theta.
4. A composition comprising the crystalline form of claim 1 .
5. A pharmaceutical composition comprising the crystalline form of claim 1 and at least one pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5 wherein the pharmaceutical composition is a solid oral composition.
7. The pharmaceutical composition of claim 6 , wherein the solid oral composition is a tablet or capsule.
8. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is a unit dose.
9. A method of treating or preventing a disease for which zoledronic acid is indicated, said method comprising the step of administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 5 .
10. The method of claim 9 , wherein said disease is selected from the group consisting of osteoporosis, hypercalcemia, cancer induced bone metastasis, Paget's disease, adjuvant cancer therapy and neoadjuvant cancer therapy.
11. The method of claim 10 , wherein said hypercalcemia is tumor induced hypercalcemia (TIH).
12. The method of claim 10 , wherein said disease is cancer induced bone metastasis.
13. A method of making the crystalline form of claim 1 , comprising the steps of: dissolving a zoledronic acid : DL-lysine water complex in acetic acid; forming zoledronic acid:DL-lysine crystals; and purifying said zoledronic acid:DL-lysine crystals from said acetic acid.
14. The method of claim 13 , wherein said method comprises the step of contacting said zoledronic acid, DL-lysine and acetic acid with an antisolvent.
15. The method of claim 14 , wherein said antisolvent is selected from the group consisting of ethanol, ethylacetate (EtOAc), isopropanol (IPA), isopropylacetate (IPAc), diethoxymethane (DEM), Toluene, BuOAc, N-methylpyrrolidone (NMP) and a heptane.
16. The method of claim 14 , wherein said antisolvent is selected from the group consisting of dimethylsulfoxide (DMSO), dioxane, NMP, dimethylformamide (DMF), dimethylacetamide (DMA), and DEM.
17. A composition comprising the crystalline form of claim 2 .
18. A composition comprising the crystalline form of claim 3 .
19. A pharmaceutical composition comprising the crystalline form of claim 2 and at least one pharmaceutically acceptable carrier.
20. A pharmaceutical composition comprising the crystalline form of claim 3 and at least one pharmaceutically acceptable carrier.